

NKI-AVL Biobank (for blood and blood products)

Published: 01-03-2010

Last updated: 04-05-2024

-

Ethical review	Approved WMO
Status	Pending
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON32651

Source

ToetsingOnline

Brief title

NKI-AVL Biobank

Condition

- Other condition
- Miscellaneous and site unspecified neoplasms malignant and unspecified

Synonym

cancer

Health condition

kanker- en therapie-gerelateerde aandoeningen

Research involving

Human

Sponsors and support

Primary sponsor: Nederlands Kanker Instituut

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: biobank, blood, DNA, serum

Outcome measures

Primary outcome

-

Secondary outcome

-

Study description

Background summary

-

Study objective

-

Study design

-

Study burden and risks

-

Contacts

Public

Nederlands Kanker Instituut

Plesmanlaan 121

1066 CX

NL

Scientific

Nederlands Kanker Instituut

Plesmanlaan 121
1066 CX
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

- newly diagnosed patient, selected tumor types
- or healthy volunteer visiting NKI-AVL

Exclusion criteria

-

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active

Primary purpose: Other

Recruitment

NL
Recruitment status: Pending
Start date (anticipated): 01-10-2009
Enrollment: 50000
Type: Anticipated

Ethics review

Approved WMO
Application type: First submission
Review commission: PTC Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis (Amsterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL29873.031.09